- Global Pharma News & Resources

Investigation Report on China's Tacrolimus Market 2021-2025 -

DUBLIN--(BUSINESS WIRE)--The "Investigation Report on China's Tacrolimus Market 2021-2025" report has been added to's offering.

According to this market research, the sales value of Tacrolimus in China has an increasing trend from 2016 to 2020, with a CAGR of approximately 13.5% from 2016 to 2020. The sales revenue of Tacrolimus in China was CNY1.57 billion in 2020.

The growth rate in 2020 was 4.8% Year on Year, which slowed down compared to that in the previous years due to the COVID-19 epidemic.

The analyst analyzes that as the epidemic situation has been improved and the hospitals resume their operation, sales of Tacrolimus will have a recovery growth from 2021 to 2025. Besides, sales will also increase due to market expansion. In light of research findings, the indication for preventing rejection in transplantation operations generates the most sales for Tacrolimus.

However, the number of new dialysis patients each year far exceeds the number of organ transplant operations, which means the demand for transplantation is not satisfied. With the development of policies and the increase in the number of organ donations, more patients will be able to receive transplants in the future, which will increase the demand for Tacrolimus.

Tacrolimus is a macrolide antibiotic and is also a new immunosuppressant. It is available in a variety of dosage forms. The ointment is used for moderate to severe atopic dermatitis where traditional therapies are not suitable, while the capsule and the injection are used to prevent graft rejection after liver or kidney transplantation. In recent years, Tacrolimus has become the first-line medication for liver and kidney transplantation. The Tacrolimus eye drop is used for vernal keratoconjunctivitis with poor anti-allergic treatment.

Tacrolimus' original drug was developed by Fujisawa Pharmaceutical, which became Astellas after the merger. Tacrolimus was launched in China in 2005. In addition to Astellas, other manufacturers in the Chinese Tacrolimus market are Hangzhou Zhongmeihuadong, LEO, Zhejiang Hisun, and Sinopharm Chuankang.

Topics Covered:

  • The impact of COVID-19 on China's Tacrolimus market
  • Sales value and volume of China's Tacrolimus 2016-2020
  • Competitive landscape of China's Tacrolimus market
  • Prices of Tacrolimus in China
  • Prices of Tacrolimus in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Tacrolimus market
  • Prospect of China's Tacrolimus market from 2021 to 2025

Key Topics Covered:

1 Relevant Concepts of Tacrolimus

1.1 Indications for Tacrolimus

1.2 Development of Tacrolimus in China

1.3 Governmental Approval of Tacrolimus in China

1.4 The Impact of COVID-19 on Tacrolimus sales in China

2 Sales of Tacrolimus in China, 2016-2020

2.1 Sales Value of Tacrolimus

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Tacrolimus

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Tacrolimus by Dosage Form in China, 2016-2020

2.3.1 Injection

2.3.2 Eye Drop

2.3.3 Capsule

2.3.4 Ointment (Cream)

3 Analysis of Major Tacrolimus Manufacturers in China, 2016-2020

3.1 Analysis of Market Share of Major Tacrolimus Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Astellas Pharma Co Ltd

3.2.1 Enterprise Profile

3.2.2 Sales of PROGRAF (Astellas' Tacrolimus) in China

3.3 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.

3.3.1 Enterprise Profile

3.3.2 Sales of Saifukai (Hangzhou Zhongmeihuadong's Tacrolimus) in China

3.4 LEO Pharma A/S

3.4.1 Enterprise Profile

3.4.2 Sales of PROTOPIC (LEO's Tacrolimus) in China

3.5 Zhejiang Hisun Pharmaceutical Co., Ltd.

3.5.1 Enterprise Profile

3.5.2 Sales of Fumeixin (Zhejiang Hisun's Tacrolimus) in China

3.6 Sinopharm Chuankang Pharmaceutical Co., Ltd.

3.6.1 Enterprise Profile

3.6.2 Sales of Yilikang (Sinopharm Chuankang's Tacrolimus) in China

4 Prices of Tacrolimus for Different Manufacturers in China, 2020-2021

4.1 Astellas Pharma Co Ltd (PROGRAF)

4.2 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (Saifukai)

4.3 LEO Pharma A/S (PROTOPIC)

4.4 Zhejiang Hisun Pharmaceutical Co., Ltd. (Fumeixin)

4.5 Sinopharm Chuankang Pharmaceutical Co., Ltd. (Yilikang)

5 Prospect of Chinese Tacrolimus drug Market, 2021-2025

5.1 Influential Factors of Chinese Tacrolimus Market Development

5.1.1 The Impact of COVID-19 on Chinese Tacrolimus Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 07-Jan-2022